Kazia Therapeutics Ltd ADR KZIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KZIA is a good fit for your portfolio.
News
-
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
-
Kazia announces presentation of new data at AACR Annual Meeting
-
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
-
Kazia Therapeutics Shares Higher Premarket on Key FDA Designation
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.37–0.40
- 52-Week Range
- $0.19–1.43
- Bid/Ask
- $0.37 / $0.41
- Market Cap
- $10.25 Mil
- Volume/Avg
- 376 / 899,576
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
|
Metric
|
KZIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KZIA
|
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 1.42 |
Interest Coverage | — |
Quick Ratio
KZIA
Profitability
|
Metric
|
KZIA
|
|---|---|
Return on Assets (Normalized) | −73.91% |
Return on Equity (Normalized) | −161.92% |
Return on Invested Capital (Normalized) | −147.35% |
Return on Assets
KZIA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bpmjhvmhw | Ybj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bcxtmpw | Bdnwnh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rvzxbwvv | Zyjpzfm | $99.5 Bil | |
MRNA
| Moderna Inc | Pzpzrwzz | Lvv | $38.8 Bil | |
ARGX
| argenx SE ADR | Gdxmhjzlc | Qwb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ssytjgpb | Zlkw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hcyxgqx | Rclxz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Prrfqfzm | Snwmn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cgfyjhjdm | Zmbff | $12.5 Bil | |
INCY
| Incyte Corp | Stylzgmz | Hhlczvj | $11.6 Bil |